Davor G.
- Country
- Croatia
- Department
- Department of hematology
Research Overview
- Phase 3 Open-Label Study of Elranatamab vs. Elotuzumab, Pomalidomide, Dexamethasone, or Carfilzomib in Relapsed/Refractory Multiple Myeloma Post Anti-CD38 Therapy
- Phase 3 Randomized Study of Navtemadlin and Ruxolitinib Versus Placebo and Ruxolitinib in Myelofibrosis Patients with Suboptimal Ruxolitinib Response
Data & Insights
Has run more than one trial at 31 of 187 partner sites.
Specializations
Hematologic Disorders
The investigator specializes in treating myelofibrosis, focusing on both primary and secondary forms of this hematologic condition.
- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis
Key interests include spleen volume management and symptom reduction in myelofibrosis patients.
Therapeutic Innovation
The investigator explores combination therapy approaches in hematologic malignancies, with particular attention to novel treatment strategies.
- Targeted Therapy Combinations
- JAK Inhibitor Enhancement
- Innovative Treatment Protocols
Areas of focus include optimizing therapeutic outcomes through strategic drug combinations.
Clinical Outcomes
The investigator evaluates treatment efficacy through specific clinical endpoints in myeloproliferative disorders.
- Spleen Volume Assessment
- Symptom Score Evaluation
- Treatment Response Monitoring
Emphasis on quantifiable therapeutic outcomes in blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.